Via Yahoo! Finance:U.S. drugmaker Pfizer is ready to launch its respiratory syncytial virus (RSV) vaccine for both older adults and pregnant women in the United States and Europe later this year, executives said on Thursday.
Both Pfizer and British drugmaker GSK have RSV vaccines they hope to launch in the United States and Europe this year, pending regulators’ approval. [emphasis added]
"We are anticipating approval in both the U.S. and Europe in time for rollout in the fall," Kena Swanson, Pfizer head of viral vaccines research & development, told a media briefing at the company’s biggest manufacturing and packaging site globally.
"Pending regulators’ approval" — haha! As if there is any doubt about which way the FDA’s decision will go, as if the agency is anything more than a ceremonial rubber-stamping formality.
Is Pfizer’s new concoction medically necessary, strictly speaking, or perhaps are there alternate motives at play?